Withdrawn
OBSERVATIONAL
NCT01470430
VEGF In Systemic Circulation Of ROP-infants
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to measure systemic levels of vascular endothelial growth factor (VEGF) and other proteins (e.g. IGF-1) in the systemic circulation of infants with retinopathy of prematurity (ROP) following ocular treatment with either intravitreal injections of anti-VEGF agents or retinal laser photocoagulation. The primary aim is to determine if serum VEGF levels change after treatment.
Primary Outcomes
Measure:
Systemic VEGF levels following treatment
TimeFrame:
16 weeks
Description:
comparing VEGF levels in serum of ROP infants treated with intravitreal anti-VEGF agents vs. retinal laser photocoagulation over 16 weeks post treatment
Trial Information
NCT ID
NCT01470430
Status
Withdrawn
Study Type
OBSERVATIONAL
Sponsor
University Hospital Freiburg
Last Updated
December 15, 2025